Amgen has launched two pivotal late-stage trials for MariTide, an experimental weight loss drug aimed at entering the growing obesity treatment market, competing against other products from Novo Nordisk and Eli Lilly.

Eli Lilly announced a plan to invest at least $27 billion in new U.S. manufacturing sites to meet the rising demand for its weight loss and diabetes drugs, amidst a backdrop of reshoring manufacturing and enhancing supply chains.

Hims & Hers Health experienced a significant 28% drop in shares following disappointing financial results, raised concerns over its weight loss business, and has decided to discontinue some products due to supply resolution.